CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension

This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension. Participants completing Treatment Period 1 (Week 36) will be re-randomized to continue or switch study treatment for Treatment Period 2 through Week 52.

NCT Number	NCT07761572
Lead Sponsor	Cereno Scientific AB
Conditions	Pulmonary Arterial Hypertension
Enrollment	126 participants
Start Date	2026-09-15
Primary Completion	2029-02-02 (estimated)
Study Completion	2029-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-12